Genetic lesions and other regulatory events lead to silencing of the 13q14 locus in a majority of chronic lymphocytic leukemia (CLL) patients. This locus encodes a pair of critical proapoptotic microRNAs, miR-15a/16-1. Decreased levels of miR-15a/16-1 are critical for the increased survival exhibited by CLL cells. Similarly, in a de novo murine model of CLL, the NZB strain, germline-encoded regulation of the syntenic region resulted in decreased miR-15a/16-1. In this paper, we have identified additional molecular mechanisms regulating miR-15a/16-1 levels and have shown that the transcription factor BSAP (B-cell-specific activator protein) directly interacts with Dleu2, the host gene containing the miR-15a/16-1 loci, and by negative regulation of the Dleu2 promoter, results in repression of miR-15a/16-1 expression. CLL patient B-cell expression levels of BSAP were increased compared with control sources of B cells. With the use of small interfering RNA-mediated repression, the levels of BSAP were decreased in vitro in the NZBderived malignant B-1 cell line, LNC, and in ex vivo CLL patient peripheral blood mononuclear cells (PBMCs). BSAP knockdown led to an increase in the expression of miR-15a/16-1 and an increase in apoptosis, and a cell cycle arrest in both the cell line and patient PBMCs. Moreover, using Dleu2 promoter analysis by chromatin immunoprecipitation assay, we have shown that BSAP directly interacts with the Dleu2 promoter. Derepression of the Dleu2 promoter via inhibition of histone deacetylation combined with BSAP knockdown increased miR-15a/16-1 expression, and also increased malignant B-cell death. In summary, therapy targeting enhanced host gene Dleu2 transcription may augment CLL therapy.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is an age-associated B-cell malignancy characterized by the accumulation of hyperdiploid B-1 cells in the bone marrow, spleen and blood. 1 It is the most common lymphoid malignancy in the western hemisphere. Since its first documented diagnosis more than 150 years ago, the etiology of CLL is largely unknown and it remains incurable with current therapy.
2 FCR therapy-combination of Fludarabine, Cyclophosphamide and Rituximab-is the new gold standard for CLL therapy. 3 Although the response rate to therapy is higher as compared with other cancers, almost all patients relapse because of persistence of minimal residual disease. 4, 5 Hence, novel treatment strategies need to be developed. Modulating microRNA expression is one such promising but underexplored therapeutic area. 6 We have previously shown that miR-15a/16-1 upregulation is one such promising therapeutic strategy. 7 The 13q14 (region that encodes miR-15a/16-1 in humans) deletion is the most common chromosomal abnormality in CLL, occurring in 50-60% of patients. 8 It is believed to encode critical tumor suppressor genes, as it is frequently deleted or silenced in various other malignancies like prostate cancer, mantle cell lymphoma and multiple myeloma. [9] [10] [11] Detailed cytogenetic analysis has revealed the presence of a 130-kb minimal deleted region centromeric to the marker D13S272 that contains several candidate tumor suppressor genes like Dleu1, Dleu2, Dleu5 and Dleu7. 12, 13 However, currently only Dleu2 (host gene of miR-15a/16-1) and Dleu7 have been demonstrated to have tumorsuppressive functions in CLL. 14, 15 MicroRNAs are often located in intronic regions within host genes, which can be both coding and non-coding host genes. 16 Mir-15a/16-1 is encoded within an intronic region of the non-coding Dleu2 gene in both human and mouse, and is transcribed off the Dleu2 promoter. A point mutation (in several CLL patients and NZB mice-de novo mouse model of CLL) and a point deletion (in NZB mice) in the 3 0 -flanking region of mir-16-1 was discovered and was associated with 50% reduction in the expression of mature miR-15a/16-1 in patients as well as in NZB mice and LNC cell line (NZB-derived mouse B-CLL line). [17] [18] [19] Correcting the reduced miR-15a/16-1 level gives rise to growth inhibitory effect. 20 To develop strategies to modulate miR-15a/16-1 levels, it is imperative to understand the molecular mechanisms that control its expression.
BSAP (B-cell-specific activator protein), encoded by the Pax5 gene, acts as a transcription factor and contains a DNA-binding domain, and recently it has been shown that BSAP negatively regulates Dleu2, the host gene of mir-15a/16-1 in mouse lymphoma cells. 21 BSAP is expressed at the pro-B-cell stage and is maintained until the plasma cell stage is reached. 22 BSAP can function either as an oncogene or a tumor suppressor depending on the cell type. 23 BSAP can result in increased or decreased gene expression and this can be regulated by additional proteins that BSAP is capable of interacting with via its protein-binding domain. BSAP overexpression generally confers proliferative phenotype in lymphoid malignancies, especially B-ALL. 24, 25 In light of this background, we explored the BSAP-Dleu2 regulation in mouse and human CLL cells. It has become increasingly clear that combination therapies are much more effective at fighting cancer (reviewed in Humphrey et al. 26 ). Hence, we also report herein the combined effect of BSAP knockdown and histone deacetylase (HDAC) inhibition (HDAC activity is increased in CLL) on miR-15a/ 16-1 levels and malignant cell death.
RESULTS
BSAP levels are increased and inversely correlate with miR-15a/16 levels in B-1 malignant cells from CLL patient PBMCs PBMCs from untreated CLL or age-matched normal controls were stained for surface expression of CD19 and CD5 and intracellular levels of BSAP. Cells were gated on CD19
þ (B-cell gate) and the mean fluorescence intensity (MFI) of BSAP determined (Figure 1a) . The BSAP levels in a non-B-cell source, patient T cells (CD3 þ , CD19 À ), is shown for comparison. The CLL B cells demonstrated increased expression of BSAP when compared with non-CLL sources. However, all sources of B cells had increased expression of BSAP relative to their T-cell population. In addition, the CLL B cells were sorted into two different B-1 populations, Figure 1b) . RNA was obtained from the sorted populations and analyzed by polymerase chain reaction (PCR) for the expression of miR-15a. The B-1 cells with high BSAP had reduced levels of miR-15a relative to the expression in B-1 cells with low expression of BSAP (Figure 1b) . Similarly, as miR-15a/16-1 targets Bcl-2, the expression of Bcl-2 was low in the BSAP low-expressing CLL cells, suggesting that the resultant high levels of miR-15a/16-1 permit these cells to readily undergo apoptosis. Indeed, the BSAP low cells are the minor population of B-1 cells in the CLL patient. Hence, we hypothesized that by knocking down BSAP via small interfering (si)BSAP, miR15a/16-1 levels will be increased and their target Bcl-2 decreased, which would lead to the induction of apoptosis.
Negative regulation of miR-15a/16-1 by BSAP can be exploited for CLL therapy CLL is a very heterogeneous disease, but downregulation of miR-15a/16-1 remains the single most commonly occurring pathological event in 470% of CLL patients. 27 Hence, we hypothesized that by attenuating the BSAP-mediated negative regulation of the promoter of the host gene for miR-15a/16-1, we can increase miR-15a/16-1 levels in ex vivo-treated patient PBMCs. Total PBMCs isolated from patient blood were used for the BSAP knockdown studies instead of purified B-1 cells, as 490% of the PBMCs were malignant CD19 þ CD5 þ B-1 cells (Figure 2a ). BSAP expression was knocked down by about 25% using siRNA-BSAP as compared with the Neg. CTRL siRNA (Figure 2d ). The reduced expression of BSAP translated into a significant increase in the expression of miR-15a/16-1 (Figure 2b þ and sorted into CD5 þ BSAP hi and CD5 þ BSAP low populations. The mean expression levels of miR-15a and Bcl2 in the sorted populations, measured using 100 cell PCR, are shown in the graph. *Po0.05, n ¼ 11, two-tailed paired Student's t-test.
In the latter case, the expression of the encoded miR would depend on the promoter status of the host gene. To confirm that BSAP regulates Dleu2 transcription (host gene for mir-15a/16-1), the Dleu2 mRNA level was measured in the CLL patient PBMCs following siRNA-BSAP. A significant increase was observed in the expression of Dleu2 following BSAP knockdown (Figure 2b ). The increase in Dleu2 was found to be positively correlated to the level of miR-15a/16-1 (Figure 2c ). Hence, we conclude that BSAP inhibits mir-15a/16-1 expression by inhibiting the transcription of its host gene, Dleu2. This was further verified by fluorescence in situ hybridization (FISH) analysis at a single-cell level to quantitate simultaneously the amount of Pax5 mRNA (which encodes the BSAP protein) and the amount of Dleu2 mRNA. In non-CLL B cells, the amount of Pax5 (BSAP) was decreased relative to the CLL B cells (Figure 3 ). In addition, the amount of Pax5 expression was inversely related to the amount of Dleu2 on a single-cell level ( Figure 3) , with CLL B cells having low levels of miR-15a/16 expression and high levels of BSAP and non-CLL B cells expressing lower levels of BSAP but higher levels of miR15a.
BSAP interacts with Dleu2 promoter It is currently unknown whether BSAP regulates Dleu2 promoter directly or indirectly. Promoter analysis using CONSITE failed to show any canonical BSAP binding sites in the human Dleu2 promoter. However, we cannot rule out the possibility that BSAP might be present in a complex with some of its binding partners at the Dleu2 promoter. Binding sites for some of the proteins that BSAP has been known to interact with were found in the human Dleu2 promoter (c-Myb, AML1 and E2F). We performed a chromatin immunoprecipitation (ChIP) assay on Daudi cells to assess BSAP-Dleu2 promoter interactions. Daudi is a B lineage cell line (Burkitt's lymphoma) and has BSAP expression. 28 Similar to the positive control of CD19 promoter, the Dleu2 promoter was enriched in the BSAP pulldown. No enrichment of the negative control Kras promoter was observed (Figures 4a and b) . The ChIP assay was performed using four CLL PBMC samples in four independent pulldown experiments ( Figure 4c ). The Dleu2 promoter region was also enriched in the CLL samples and was similar to a known promoter, which encodes a BSAP binding site, 
the CD19 promoter. In contrast, the Kras promoter, which does not encode a BSAP binding site, was not pulled down in CLL samples ( Figure 4c ). These data suggest that a BSAP binding site is present at the Dleu2 promoter in human B cells. However, a canonical BSAP binding site was found at þ 676 position in the mouse Dleu2 gene. A ChIP assay was performed on murine B cells, the LNC cells, to assess BSAP-Dleu2 promoter interactions. As we knew the position of the putative BSAP binding site in mouse Dleu2, we were able to design a ChIP assay having an internal control in addition to the glyceraldehyde 3-phosphate dehydrogenase control as shown in Figure 4d . Indeed, the Dleu2 promoter fragments were enriched in the BSAP pulldown and the amount of enrichment was inversely proportional to the distance from the BSAP binding site (Figure 4e ). The upstream sequences (U) were not as enriched by the BSAP pulldown as were the downstream sequences (D), which contained the BSAP binding site. The presence of the Dleu2 U region in the BSAP pulldown may be because of DNA fragments, which contain both the D and U region. The human data indicating BSAP interaction with the Dleu2 promoter were validated in the mouse system, which has a canonical BSAP binding site in its promoter.
BSAP knockdown leads to cell cycle arrest and apoptosis in NZB We and others have previously shown that miR-15a/16-1 expression is reduced by almost 50% in CLL (in both patients and NZB mice). 20 Using microarray-based expression analysis, negative correlation was shown between BSAP and Dleu2 (host gene of miR-15a/16-1) levels in Myc5 cells. 21 Myc5 is a B-lymphoma cell line derived by transducing p53-null bone marrow cells with c-Myc retrovirus. These cells can oscillate between B-cell and macrophage lineages based on the culture conditions and BSAP levels in vitro. 29 On the contrary, LNC is a natural malignant B-1 cell line derived from the spontaneously Figure 3 . In situ RNA FISH analysis of Dleu2 and Pax5 mRNA levels. Cells were grown on poly L-lysine-coated coverslips and hybridized with single-molecule FISH probes. Dleu2 probes were labeled with TMR and Pax5 probes were labeled with Alexa 594. The z-stacks obtained from each fluorescence channel were merged and coded to represent Pax5 (in red) and Dleu2 (in green). Each spot represents single mRNA molecule. 65 The right panel shows the merger of both channels and the chart represents the mean values from multiple analysis ± s.e.m. occurring murine model of human CLL and has constitutively very high levels of BSAP expression and low levels of miR-15a/16-1 expression (Supplementary Figure S1) . In light of the above disparities in the two systems, we wanted to confirm whether BSAP could negatively regulate miR-15a/16-1 levels in our system. The NZB-derived CLL cell line LNC was transfected with either 3 mg non-targeting negative control siRNA (Neg.CTRL) or with 3 mg siRNA BSAP (siRNA-BSAP), using Amaxa Nucleofection (Lonza, Walkersville, MD, USA), to transiently knockdown BSAP. The expression of BSAP was reduced as early as 12 h post-transfection and the suppression began to diminish after 48 h. Flow cytometric analysis via histogram overlays of BSAP levels on a per cell basis showed a decrease in BSAP in siRNA-treated cells compared with Neg.CTRL-treated cells as early as 12 h post-transfection (Figure 5a ). The average BSAP MFI at different time-points posttransfection is shown in Figure 5b and was found to be lowest at 24 h post siRNA-BSAP treatment when compared with the Neg.CTRL at that time-point (Po0.05). BSAP protein was reduced by 53% at 24 h as compared with the Neg.CTRL. The miR-15a levels were measured in cells with successful knockdown of BSAP to determine the potential causal relationship between BSAP and miR-15a/16-1 expression in our system. The miR-15a level was measured using TaqMan MicroRNA Assays (Applied Biosystems, Carlsbad, CA, USA) and an approximately twofold increase in miR15a levels was observed in the siRNA-BSAP-treated cells at 24 h (Po0.05) (Figure 5c ). Interestingly, the increase in miR-15a expression corresponded with the peak reduction in BSAP, suggesting a strong influence of BSAP on the expression of the microRNA. LNC cells mimic aggressive CLL and are very rapidly dividing. We and others have shown that an increase in miR-15a/ 16-1 leads to cell cycle arrest and reduced proliferation. [30] [31] [32] Initially, we have shown that reducing BSAP levels results in an increase in miR-15a/16-1 expression. To test the biological significance of this, the increased miR-15a/16-1 should result in decreased downstream targets like cyclin D, leading to cell cycle arrest. As compared with the Neg.CTRL-treated cells, which have baseline level of BSAP and miR-15a/16-1, the siRNA-BSAP-treated cells exhibited a significant increase in the percentage of cells in the G1 phase and a reduction in the percentage of cells in the S phase (Figures 5d and e, Po0.05) . Moreover, we also observed a decrease in the expression of cyclin D1 in the siRNA-BSAP-treated cells as compared with the Neg.CTRL-treated cells (Figure 5f ), indicating that the cell cycle arrest is a direct consequence of increased miR-15a/16-1, as it has been shown to be an important regulator of cyclin D1.
Combination treatment with HDAC inhibitor Next, we wanted to assess whether the antiproliferative effect of BSAP knockdown can be enhanced by using an HDAC inhibitor. LNC cells were treated with siRNA-BSAP and the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) (clinically known as vorinostat). Dose-response curves were calculated for SAHA (data not shown) and a suboptimal dose of 0.8 mM was selected for the combination treatment. An additive effect was observed on the increase in the %G1 (Figure 6a ) and decrease in %S (Figure 6b ) as compared with the untreated cells. However, a synergistic effect was observed in the percentage of cells undergoing apoptosis when treated with the siRNA BSAP and SAHA together (Figure 6c ). In addition, we observed a significant increase in miR-15a/16-1 expression following treatment (Figure 6d ). To confirm that the observed cell cycle and apoptosis effects are mediated by (Figure 6e ). This gave rise to a partial rescue from increased malignant cell death (Figure 6f ). In conclusion, these findings indicate that the combination of HDAC inhibition and BSAP knockdown leads to a significantly higher increase in malignant cell death in part by increasing the level of miR-15a/16-1.
DISCUSSION
In this study, we found that in CLL patients, B cells constitutively express higher levels of BSAP than do control sources of B cells. However, within a CLL malignant clone, a minority of the B-1 cells had relatively low levels of BSAP. Analysis of the two types of B-1 cells demonstrated that increased expression of the microRNA miR15a/16-1 was found in the patient B-1 subpopulation with the higher expression of BSAP (minor population). To further dissect the role of BSAP in the regulation of the levels of miR-15a/16-1, addition of siRNA pools with antisense regions to the Pax5 gene (which encodes BSAP) resulted in an increase in miR-15a/16-1 levels. Taken together, these studies indicate that BSAP is a negative regulator of miR-15a/16-1. The BSAP-mediated regulation of miR-15a/16-1 levels is occurring at the level of the host gene transcription as seen by the significant positive correlation between Dleu2 and miR-15a/16-1 levels that is dependent on the BSAP levels and independent of downstream mutations in that loci. This was also observed at the level of single-cell RNA FISH analysis. We have also shown that BSAP interacts with the Dleu2 promoter (direct interaction in mice and indirect interaction in humans). This finding is very interesting given that the human Dleu2 promoter lacks a canonical BSAP binding site. We speculate that BSAP interacts with another protein that binds to the Dleu2 promoter directly and this complex is responsible for the repression of the Dleu2 promoter. This report concentrated on Dleu2 promoter repression and other studies have also indicated that the Dleu2 promoter regulates miR15a/16 levels. 33 However, a potential promoter region located near the mir15a/16-1 loci within Dleu2, which has myb binding sites, has been reported and myb interacts with BSAP. 34 Further studies need to be performed to identify binding partners of BSAP and additional promoter regulation of miR15a/16.
Earlier studies focused mainly on the role of BSAP in the B-cell lineage development program. 35 This study highlights the role of BSAP in cancer cell survival via its regulation of an important pro-apoptotic microRNA cluster, mir-15a/16-1. BSAP appears to act as an oncogene in CLL and has an important role in downregulating mir-15a/16-1, a known tumor suppressor in CLL. Other groups have also demonstrated the role of BSAP in regulating apoptosis. 36 Previously, we demonstrated that inhibition of BSAP leads to decreased proliferation and apoptosis in malignant B-1 cells from the NZB murine model of CLL. [37] [38] [39] In this study, we have shown that knocking down BSAP leads to malignant cell death not only in our murine CLL cell line but also in ex vivo patient PBMCs via upregulation of miR15a/16 levels. We propose that targeting BSAP using siRNA or small-molecule inhibitors could serve as a novel therapeutic strategy for CLL. The role of BSAP in tumorigenesis is highly cell type specific, in that it can act both as an oncogene (non-Hodgkin's lymphoma, neuroblastoma) or as tumor suppressor (multiple myeloma). [40] [41] [42] [43] Targeting BSAP has already been shown to have therapeutic effects in other types of cancers like small-cell lung cancer. 44 BSAP has been shown to be a positive regulator of CD19 and indirectly to control c-myc levels via regulation of CD19. 45 In these studies, BSAP binding to the promoter region of CD19 in the ChIP analysis was verified and the additional binding to the promoter of Dleu2 (and miR15a/16-1) determined. The elevated levels of BSAP found in CLL malignant B-cell clones may have multiple effects in addition to negative regulation of miR15a/16 via repression of Dleu2 including elevation of c-myc via upregulation of CD19.
Because the bicistronic miR-15a/16-1 is a tumor suppressor microRNA, 46 a wide variety of malignancies involve the repression of this microRNA cluster. There are different mechanisms by which this repression occurs. Several other studies have also found that the Dleu2 host gene promoter is repressed. Recently, c-Myc has been shown to repress the Dleu2 promoter via recruitment of HDAC3. 47 HDAC activity is increased in a variety of cancers including CLL. [48] [49] [50] HDACs have emerged as attractive targets in the treatment of both solid and hematological malignancies. [51] [52] [53] Several groups have reported the efficacy of HDAC inhibitors in inducing CLL cell death in vitro and in clinical trials. 54, 55 In addition to inducing direct cell death, HDAC inhibition also increases the immunogenicity of CLL cells, thereby facilitating antitumor immune response. 56, 57 HDAC has also been shown to repress the Dleu2 promoter in CLL malignant B-1. 58 Our results support these previous findings. We have shown that similar to BSAP-mediated Dleu2 repression, HDAC-mediated repression is also reversible and it opens up avenues for therapeutic intervention. Based on the data presented in this paper, we propose that BSAP and HDACs co-operate to bring about repression of the Dleu2 promoter in CLL. This study is critical because for the first time it simultaneously addresses the interaction between three important players (13q14 locus, BSAP and HDAC) involved in CLL pathogenesis. Out of the many genetic alterations found in CLL, the frequency of only 13q14 deletions is significantly elevated in MBL (monoclonal B-cell lymphocytosis), the precursor stage of CLL. 59 In addition, epigenetic silencing of 13q14 has been found in CLL. 60 This finding indicates that 13q14 silencing via its deletion or epigenetic modification is one of the first events leading to CD19 þ CD5 þ B-cell expansion and understanding the regulation of this locus will be instrumental in delineating CLL etiology. A recent paper by Laurie et al. 61 that analyzed clonal mosaicism in 50 000 subjects further underscores the importance of the 13q14 region in CLL. 61 In this study, the authors discovered that 13q deletions were overrepresented in normal subjects with age and its presence increased the chances of a future CLL diagnosis.
In summary, we have shown that in CLL, promoter regulation by a transcriptional repression via BSAP and HDAC co-coordinately repress Dleu2, the host gene of miR-15a/16-1, and targeting this loop leads to malignant cell death via increase in mature miR-15a/ 16-1 expression (Supplementary Figure S2) .
MATERIALS AND METHODS

Patient samples and cell lines
A measure of 4-5 ml of blood was collected in ethylenediaminetetraacetic acid (EDTA) tubes from untreated CLL patients after obtaining informed consent in accordance with UMDNJ (now Rutgers) and East Orange Veterans Administration New Jersey Health Care System human subjects Institutional Review Board. PBMCs were isolated from patient blood using Ficoll-Hypaque solution according to the manufacturer's instructions (Stem Cell Technologies Inc., Vancouver, BC, Canada). Human Burkitt's lymphoma cell line Daudi (ATCC No. CCL-213, Manassas, VA, USA) was used. In addition, the NZB-(murine model of human CLL) derived malignant B-1 cell line LNC was also used. 62 Both cell lines were maintained in RPMI 1640 supplemented with 10% fetal bovine serum, 1% sodium pyruvate, 1% penicillin-streptomycin at 37 1C and 5% CO 2 . Sorting of B-1 cells and 100 cell PCR CLL patient PBMCs were stained with CD19-FITC, CD5-PE.Cy7 and BSAP-PE antibodies. The CD19 þ population in the lymphoid gate was further sorted into CD5
þ BSAP hi (B-1 BSAP hi) and CD5 þ BSAP low (B-1 BSAP low) using the BD FACS Aria II cell sorter. Owing to the low number of cells obtained after sorting, we performed 100 cell PCR to measure the miR-15a/16-1 and Bcl-2 levels in the sorted subpopulations. Briefly, for the microRNA measurement, 100 cells in 4.84 ml 1Â phosphate-buffered saline were heat disrupted at 95 1C for 10 min to release RNA and immediately kept on ice. This extract was then used to prepare cDNA using the TaqMan microRNA RT Kit (Applied Biosystems), followed by real-time PCR. Bcl-2 levels were measured using the Power SYBR Green Cells-to-Ct Kit (Ambion Inc., Austin, TX, USA).
RNA isolation and quantitation
Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. MicroRNA-specific cDNA was prepared using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's instructions. The following pre-made TaqMan Assays (Applied Biosystems) were used for real-time quantitation-mmu-miR-15a (Assay ID 000389) and U6 (Assay ID 001973). Dleu2 transcripts were quantified from random hexamer-primed cDNA using TaqMan hsa-Dleu2 Assay (Applied Biosystems) (Assay ID Hs00863925 m1). MicroRNA and Dleu2 levels were normalized to U6 (mouse and human) and 18s rRNA (human), respectively.
Cell cycle and apoptosis assay
For cell cycle analysis, 0.5 Â 10 6 were washed with 1 Â phosphate-buffered saline and resuspended in 300 ml hypotonic propidium iodide solution, acquired on a BD Calibur IV cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and analyzed using the ModFit LT Software (Verity Software House, Topsham, ME, USA). For apoptosis quantitation, cells were stained with Annexin V-PE (BD Bioscience) according to the manufacturer's protocol, acquired on BD Calibur IV.
Chromatin immunoprecipitation
In total, 5 Â 10 6 cells were crosslinked with 0.37% formaldehyde and sonicated to obtain 1-kb or 400-bp fragments using the S220 sonicator (Covaris Inc., Woburn, MA, USA). The ChIP-ready chromatin was pulled down with either goat anti-human Pax5 (Santa Cruz Biotechnology) or normal goat immunoglobulin G (IgG) (Santa Cruz Biotechnology). EpiTect One Day ChIP Kit (Qiagen) was used. The pulled down DNA was then used for real-time SYBR Green PCR of Dleu2 promoter using primers described in Bougel et al. 63 CD19 promoter was used as a positive control and Kras promoter was used as the negative control. Similar protocol was followed for the mouse cell line. Dleu2 was primed at two separate sites (with and without the BSAP binding site as an internal control). CD19 was used as a Activating miR-15a/16 host gene promoter in CLL S Kasar et al positive control and glyceraldehyde 3-phosphate dehydrogenase was used as a negative control. Refer Supplementary materials (Supplementary Table  S1 ) for mouse primer sequences.
HDAC inhibitor treatment SAHA (clinically known as vorinostat 57, 64 ) (Selleckchem, Houston, TX, USA) was dissolved in 100% ethanol to obtain a 10 mM stock. The final working concentration used was 0.8 mM.
RNA FISH
Dleu2 and Pax5 RNAs were imaged using single-molecule FISH probes as described previously. 65 Briefly, a set of 35 probes was designed to hybridize to each target RNA and was synthesized with a 3 0 amino modification from Biosearch Technologies (Novato, CA, USA). The individual probes for a given target were pooled in equimolar amounts and then coupled with succinimidyl ester of either TMR (for Dleu2) or Alexa 594 (for Pax5). The coupled fraction was purified using high-performance liquid chromatography and the concentration was determined using nanodrop. The coverslips were washed with 1 Â phosphate-buffered saline, fixed in 4% formaldehyde, permeabilized with 70% ethanol and hybridized with the Dleu2 TMR and Pax5 Alexa 594 probes. Hybridization was carried out overnight at 37 1C. The coverslips were washed (with 10% formamide in 2 Â SSC) to remove unbound probes and imaged using Zeiss wide field fluorescence microscope (Carl Zeiss, Thornwood, NY, USA). For each image, z-stacks were obtained and merged to get the final image. The image acquisition was carried out by Openlab software (Perkin-Elmer, Waltham, MA, USA) and numbers of mRNAs were counted using custom written alogrithms in MATLAB (MathWorks, Natick, MA, USA). 66 
Statistics
Data were analyzed with a paired Student's t-test, unless otherwise specified. Po0.05 was considered significant.
